   Program Organisers Abstracts Participants |
2006
Brugge/Bruges, Belgium
| Al Za’abi MA (1), Xiaonian X (2), Donovan T (3), Charles BG (1) Use of Routine Data for Determination of the Population Pharmacokinetics and Enteral Bioavailability of Phenytoin in Neonates and Infants with Seizures |
| Bertrand, Julie, Emmanuelle Comets, France Mentré Detecting a gene effect in pharmacokinetic models: comparison of different methods |
| Bogacka, Barbara (1) Maciej Patan (2) Efficient Sampling Windows for Parameter Estimation in Population Models |
| Boström, Emma, Ulrika S. H. Simonsson and Margareta Hammarlund-Udenaes In vivo blood-brain barrier transport of oxycodone in the rat – active influx and implications for PK/PD |
| Brendel, Karl(1,3), Céline Dartois(2,3), Emmanuelle Comets(1), Christian Laveille(4), Annabelle Lemmenuel-Diot(3), Brigitte Tranchand(2,6), Pascal Girard(2,5), Céline Laffont(3), France Mentré(1) Are population PK/PD models adequately evaluated? An exhaustive survey of the literature between 2002 and 2004 |
| Prins, K (1), B. Poland (1), V. Nicolas (2), H. Porchet (2), P. Scalfaro (2), R. Bruno (1) Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients |
| Claret, L. (1), P. Girard (2), K.P. Zuideveld(3), K. Jorga (3), J. Fagerberg (3), R. Bruno (1) A longitudinal model for tumor size measurements in clinical oncology studies |
| Gaynor, Clare (1), Dunne, Adrian (1) and Davis, John (2) Comparison of conventional In Vitro - In Vivo Correlation methodology with non-linear mixed effects modelling |
| Bulitta, J.(1), T. P. Lodise(2), G. L. Drusano(3), M. Kinzig-Schippers(1), U. Holzgrabe(4), F. Sörgel(1,5) Bias and Uncertainty of Monte Carlo Simulations with Beta-Lactams |
| Carlsson, Kristin C., Radojka M. Savic, Andrew Hooker, Mats O. Karlsson. Mixture models in NONMEM - how to find the individual probability of belonging to a specific mixture, and why this can be useful information |
| Chantel, S.(1,2), P. Martin(1,2), P.Y. Petit (3), D. Massignon(4), X. Dode(1), P. Maire (5), R.W. Jelliffe(6), G. Aulagner(1,2) Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis |
| Nekka, Fahima (1,2), Caroline-E. Petit-jetté (1), Jun Li (1,2), Denis Gohore Bi (1), Renée Bergeron (3), Jérome del Castillo (4) Therapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline |
| Armendariz Y2, Caldes A2 , Colom H1, Gilvernet S2, Peraire C1, Domenech J1, Grinyó JM2, Wilkins J3, Karlsson M3. Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus |
| Comets, Emmanuelle(1) and Céline Verstuyft (2) Analysis of digoxin data using Non-Parametric Maximum Likelihood (NPML) |
| Cronier, D. (1,5), E. Grenier (2), M. Lecomte (3), V. Autier (3), B. Ladstetter (4), L. J. Aarons (5), and J.P. Boissel (1) Modelling of insulin secretion: from beta-cell physiology to sulphonylurea-mediated insulin secretion |
| Dansirikul, C. H.E. Silber, M.O. Karlsson Comparison of models for baseline |
| Dartois, C (1)(4), K Brendel (2)(4), E Comets (2), C Laveille (3), C Laffont (4), B Tranchand (1)(5), F Mentré (2), A Lemenuel-Diot (4), and P Girard (1)(6). How is model building reported for population PK-PD? An exhaustive survey of the literature between 2002 and 2004 |
| Dehez, Marion(1)(2)(3), Marylore Chenel(1), Roeline Jochemsen(1), Stéphanie Ragot(2) Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers |
| GastroPlus GastroPlus |
| Dodds, M.G. (1), J.E. Visich(1), I. Nestorov(1), R. Overgaard(2), M.C. Rogge(1) Population pharmacodynamic model of the effects of recombinant human interleukin 21 on platelets in humans |
| Dokoumetzidis, Aris and Leon Aarons Direct application of Bayes theorem for the combination of population pharmacokinetic analyses. |
| Duffull, S B (1), G Graham (2), K Mengersen (3) Bayesian Estimation of Optimal Sampling Times for Pharmacokinetic Models |
| Edginton, A.N.(1), S. Willmann (1), Sevestre, M (2), Kirchheiner, J (3) Determining the effect of CYP2C9 genotypes on diclofenac metabolism using individualized coupled physiology-based pharmacokinetic modeling |
| Edginton, A.N. (1), S. Willmann (1), M. Kleine-Besten (2) Use of a physiology-based whole-body population model to simulate the influence of anthropometric-, clearance-, and physiological-variance on the pharmacokinetics of drugs |
| Elsherbiny, D.(1), S. Asimus(2), M.O. Karlsson(1), M. Ashton(2), U. S. H. Simonsson(1) Modeling of the induction of CYP2B6 and CYP2C19 by artemisinin antimalarials |
| ICON Development SolutionsTM Hands-On Demonstration of PDx-Pop® v2.0; Tools for Expediting Population Analysis |
| Friberg, Lena E.(1), An M. Vermeulen(2), Mats O. Karlsson(1) A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment |
| Gibiansky, Ekaterina (1), Leonid Gibiansky (2) Model-Based Drug Development: Optimization of AQUAVAN® Injection Dosing for Minimal-to-Moderate Sedation |
| Gibiansky, Leonid, Marc R. Gastonguay R/NONMEM Toolbox for Simulation from Posterior Parameter (Uncertainty) Distributions |
| Grasela, Thaddeus(1), Jill Fiedler-Kelly(1), Cynthia Walawander(1), Charles W. Dement(2) Challenges in the Transition to Model-Based Development |
| Gupta, M, K Wade, B Jayaraman, J Mondick, JS Barrett Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions |
| Guzy, Serge Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/ Pharmacodynamic (PK/PD) Data |
| Guzy, Serge The PDX-MC-PEM software |
| Hempel, Georg; Lanvers-Kaminsky, Claudia; Ahlke, Elvira; Müller, Hans-J.; Würthwein, Gudrun; Boos, Joachim A Population Model Describing the Activity-time Course of Pegylated Asparaginase in Children |
| Hénin, Emilie(1), Klaas P. Zuideveld (2), Céline Dartois (1), Brigitte Tranchand (1,3), Gilles Freyer (1,4), Pascal Girard (1,5) A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine |
| Hennig, S. (1,2), Wainwright, CE. (3), Bell, SC. (4), Miller, H. (2) Friberg, LE. (1) and Charles, BG. (1) Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients |
| Hennig, S. (1,2), Waterhouse T.(1) Wainwright C.(3), Bell S.(4), Miller H. (2), Charles B.(1) and Duffull S.(1) A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis |
| Hing, Jeremy(1), Juan Jose Perez-Ruixo(1), Kim Stuyckens(1), Peter Zannikos(1), Arturo Soto-Matos(2), César Picó(2), Antoine Yver(1) and Andrew Chow(1) Population PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects |
| Holford, Nick, Carl Kirkpatrick, Steve Duffull NONMEM Termination Status is Not an Important Indicator of the Quality of Bootstrap Parameter Estimates |
| Hooker, Andrew, Christine E. Staatz and Mats O. Karlsson. Conditional weighted residuals, an improved model diagnostic for the FO/FOCE methods. |
| Hutmacher, Matthew M , Anand Vidyashankar, and Debu Mukherjee Model Selection Using the Minimum Hellinger Distance Criterion (MHDC) with an Introduction to Minimum Hellinger Distance Estimation (MHDE) |
| Hutmacher, Matthew M, Sriram Krishnaswami An extension of the indirect response models to ordered categorical pharmacodynamic data using latent variables |
| Jelliffe, R., A Schumitzky, D Bayard, R Leary, M Van Guilder, A Gandhi, M Neely, and A Bustad. The USC*PACK BigWinPops and MM-USCPACK Software |
| Joerger, M., A.D.R. Huitema, V. D. Doodeman, H. Boot, R. W. Sparidans, J.H. Beijnen, J.H.M. Schellens Epirubicin pharmacokinetics-pharmacodynamics and metabolic pathway-associated gene polymorphisms: Significant influence of the novel UDP-glucuronosyltransferase 2B7 promoter mutation -66T>C |
| Karlsson, Mats O. and Radojka Savić Overview of oral absorption models and modelling issues |
| Hamrén, Bengt(1), Elisabeth Björk (1), Mats O. Karlsson (2) Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients |
| Kowalski, Kenneth G., Stephen Olson, Ann Remmers A Modeling and Simulation Case Study: Impact on an Early Clinical Development Program |
| Kuester, K(1), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3) Population Pharmacokinetic Analysis for Matuzumab (EMD 72000) – A Humanised EGFR-Targeted Monoclonal Antibody |
| Landersdorfer, C.(1), C. M. J. Kirkpatrick(2), M. Kinzig-Schippers(1), J. Bulitta(1), U. Holzgrabe(3), F. Sörgel(1,4) New Insights into the Most Commonly Studied Drug Interaction with Antibiotics: Pharmacokinetic Interaction between Ciprofloxacin, Gemifloxacin and Probenecid at Renal and Non-renal Sites |
| Langdon G (1), Gueorguieva I (2), Aarons L (3), Karlsson MO (1) Linking preclinical and clinical whole body physiologically-based pharmacokinetic models with prior distributions in NONMEM |
| Lavielle, Marc (1,2,3) Hector Mesa (1) Julie Bertand (4) Adeline Samson (4) France Mentré (4) and the Monolix group Analysing population PK/PD data with the MONOLIX software |
| Leary, Robert H. and Dunlavey, Michael Parallel Processing for Nonlinear Mixed Effects Modeling |
| Lehr, T. (1), A. Staab (2), C. Tillmann (2), D. Trommeshauser (2), A. Raschig (2), H.G. Schaefer (2), C. Kloft (1,3) Efficacy modelling of NS2330 in mild Alzheimer’s disease patients |
| Lehr, T.(1), A. Staab (2), C. Tillmann (2), D.Trommeshauser (2), A. Raschig(2), H.G. Schaefer (2), C. Kloft (1,3) Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients |
| Zeumer, D., A. Staab, T. Lehr, C. Tillmann, K.-H. Liesenfeld, H. G. Schaefer PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company |
| Lindbom, Lars(1), Justin J Wilkins(1), Nicolas Frey(2), Mats O Karlsson(1), E Niclas Jonsson(1,2) Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis |
| Lopez-Pintor E (1), Valenzuela B (1), Montesinos A (2), Martín-Villodre A (2), Casabó V.G (2) Population pharmacokinetics approach for salbutamol sulphate in rats |
| Lovern, Mark R , Ginny Schmith, George Dukes, David McSorley Using a Placebo Response Model to Optimize Clinical Trial Designs for Irritable Bowel Syndrome (IBS) Therapies |
| Marshall, Scott1, Mike K Smith1, Eugene Cox2,3 and Jaap Mandema2,4 Application of PK/PD modelling in the development eletriptan DR for the treatment of acute migraine and prevention of headache recurrence. |
| Matthews, Ivan (1), Smith, Fang Gao (2), Aarons, Leon (1) Pharmacokinetics of a single bolus of propofol in Chinese children of different ages |
| Matthews, Ivan and Aarons, Leon A population pharmacokinetic model for s-warfarin: application of a mixture model to determine genotype/phenotype. |
| Miller, Raymond , Howard Bockbrader, Sunny Chapel. Comparision of Pregabalin and Gabapentin Pharmacodynamics in Patients with Refractory Partial Seizures. |
| Mills, Richard (1,2), Kayode Ogungbenro (1) & Leon Aarons (1) Simultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data |
| Mondick, John T.(1), Leonid Gibiansky (2), Marc R. Gastonguay (2), Gareth J. Veal (3), Jeffrey S. Barrett (1) Acknowledging Parameter Uncertainty in the Simulation-Based Design of an Actinomycin-D Pharmacokinetic Study in Pediatric Patients with Wilms’ Tumor or Rhabdomyosarcoma |
| Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4) A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients |
| Nalda-Molina, R (1), Bermejo M. (2), Casabó V.G. (2) A simple physiological-pharmacokinetic model to simulate bioequivalence trials |
| Fernández-Teruel C, Navarro-Fontestad MC, González-Álvarez I, Bermejo M, Casabo VG Sparse sampling designs: a new method for estimating the complete AUC and its standard error |
| Nestorov, I.1, A. Munafo2, O. Papasouliotis2, J. Visich1 and M. Rogge1 Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA) |
| Nielsen, Elisabet I(1), Uwe Ewald (2), Lena E Friberg (1) Population Pharmacokinetics of Gentamicin in Preterm and Term Newborn Infants |
| Olofsen, E. Using the Lasso to simultaneously identify the covariate and variance-covariance structures of nonlinear mixed-effects models |
| Ortega, Ignacio , An Vermeulen, Vladimir Piotrovsky Concentration-response analysis of antipsychotic drug effects using an indirect response model |
| Paccaly, A (1), Speth, H (2), Jensen, BK (1), Maas, J (2) Non-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects |
| Panhard, Xavière and Adeline Samson Extension of the SAEM algorithm for the estimation of Inter-Occasion Variability: application to the population pharmacokinetics of nelfinavir and its metabolite M8 |
| Perez Ruixo, Juan Jose Optimizing the Design of Phase I Studies of Erythropoietin Receptor Agonist Through Mechanism-Based PK/PD Modeling and Simulation |
| Marchand, M. (1), O. Petricoul (1), E. Fuseau (1), D. Bentley (2), D. Critchley (2) Extrapolation from preclinical PKPD data to clinical response, Application to a new antiepileptic medication (drug X) |
| Pihlgren, Pontus, Lars Lindbom, Niclas Jonsson Transforming a set of office computers to a computing cluster. |
| Post, T.M.(1), J.I. Freijer (1), W. de Winter (1), B.A. Ploeger (1,2) Accurate Interpretation of the Visual Predictive Check in order to Evaluate Model Performance |
| Mango Solutions Mango Solutions |
| Quartino, Angelica L., Lena E. Friberg, Mats O. Karlsson A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model |
| Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(1), Jiménez Torres N.V.(2), Semi-mechanistic KPD model for haematological toxicity in breast cancer patients receiving high dose of chemotherapy |
| Renard, D.(1b), J. Witcher (1a), Y. Nie (2), F. Vandenhende (1b), A. Kumar (3), J. Miller (1a), J. Tauscher (1a), Y. Zhou (3), D. Wong (3) Bayesian Hierarchical Modeling of Receptor Occupancy in PET Trials |
| Dittberner, S.(1), V. Duval (2), A. Staab (2), H. Fuchs (2), M. Tadayyon (2), U. Graefe-Mody (2), H.G. Schaefer (2), U. Jaehde (1) Pre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor |
| Retout, Sylvie, Emmanuelle Comets, Hervé Le Nagard and France Mentré New features for population designs evaluation and optimisation in R: PFIM 2.0 and PFIMOPT 2.0 |
| Ribbing, J. (1), J. Nyberg (1), O. Caster (1), E.N. Jonsson (1,2) The LASSO - A Novel Method for Predictive Covariate Model Building in Nonlinear Mixed Effects Models |
| Rostami-Hodjegan, A. Complications in assessing the hepatic first-pass component of bioavailability |
| Prémaud, A(1), Van Guilder M (2), Armstrong VW (3), Weber LT(3), Ghandi A (2), Oellerich M (3), Tonshoff B (3), Jelliffe R (2), Marquet P (1), Rousseau A (1) Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in paediatric renal transplant recipients using a non-parametric approach. |
| Djebli, Nassim 1, Pierre Marquet1,2, Yann Le Meur1,3, Annick Rousseau1,4 Population pharmacokinetics of sirolimus in adult renal transplant patients and Bayesian estimation of individual systemic exposure |
| Rostami-Hodjegan A, Rowland-Yeo K, Jamei M Simcyp - a platform for simulation and prediction of in vivo drug disposition in virtual human populations |
| Roy, A. and M. Pfister Optimizing Dose Selection With Respect to Multiple Safety/Efficacy Endpoints Using Clinical Utility Concepts |
| Roy Pierre, Annabelle Lemenuel-Diot, Marylore Chenel Is it possible to perform equivalent simulations with NONMEM and TS2? |
| Samson, Adeline (1), Marc Lavielle (2) and France Mentré (1) The SAEM algorithm for non-linear mixed models with left-censored data and differential systems: application to the joint modeling of HIV viral load and CD4 dynamics under treatment |
| Hussein, Ziad(1), Brigitte Lacroix(2), Maria-Laura Sargentini-Maier(2) Population pharmacokinetics of the new antiepileptic drug brivaracetam |
| Savic, Radojka M. , Maria C. Kjellsson, Mats O. Karlsson Evaluation of the nonparametric estimation method in NONMEM VI beta |
| Silber, Hanna E., Maria C. Kjellsson and Mats O. Karlsson The likelihood ratio test appears robust to most residual error model misspecifications |
| Holford, Nick, Goonaseelan (Colin) Pillai, Sandip Roy, Andrej Skerjanec, Serge Cremers, William Collins, Jean-Louis Steimer Population pharmacokinetics of balicatib, a cathepsin K inhibitor |
| Holford, Nick, Goonaseelan (Colin) Pillai, Nitin Kaila, William Collins, Sandip Roy, Serge Cremers, Ulrich Trechsel, Florilene Bouisset, Jean-Louis Steimer PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx |
| Tajima, Takeshi(1), Akihiro Yokoi (1), Peiming Ma (2), Ryosei Kawai (1) Population approach to assess the relationship of cyclosporin exposure and renal dysfunction in Japanese patients with rheumatoid arthritis |
| Testart, D.(1), G. Blanc(2), P. Delrat(1), T. Shepard(1) Development of a tool to simulate intra-individual variability encountered in animals from standard preclinical toxicological study |
| Thomas, F.(1), S Séronie-Vivien(1), F Bouissou(2), M Tafani(2), JP Delord(1), L Gladieff(1), E Chatelut(1) Cystatin C as a new covariate to predict the renal elimination of drugs |
| Tousset, E.(1), H. Figueiredo (2),M.P. Schneider(2),O. Bugnon(2), B.Vrijens (1) Relation between patients’ variable compliance and office blood pressure in treatment-resistant hypertension. |
| Lindbom, L.(1), K. Tunblad(1), L. McFadyen(2), E.N. Jonsson(1), S. Marshall(2), M. O. Karlsson(1) The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data |
| Valle M, Grasa E, Yritia M, Romero S,, Barbanoj MJ. Population Pharmacokinetic-Pharmacodynamic modelling of olanzapine effects on the electroencephalogram in healthy volunteers. |
| van Eijkeren, J.C.H. (1), M.J. Zeilmaker (1), C.A. Kan (2), L.A.P. Hoogendoorn (3) and W.A. Traag (3) Model building and model parameter identification for transfer of dioxin TEQs from feed to eggs. |
| van Hest, Reinier1, Teun van Gelder1,2, Arnold Vulto1, Leslie Shaw3, Ron Mathôt1 Pharmacokinetic modeling of plasma protein binding of mycophenolic acid in renal transplant recipients |
| Verbeke, Geert Mixed models for the analysis of categorical repeated measures |
| Viberg, Anders (1), Otto Cars (2), Mats O. Karlsson (1) and Siv Jönsson (3) Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function |
| Vicini, Paolo The Population Approach Identity Crisis: The Search For Innovation In Modeling And Simulation |
| Vicini, Paolo and the Resource Facility for Population Kinetics (RFPK) The System for Population Kinetics (SPK) |
| Barrett, Jeffrey S. PhD, FCP1, Kalpana Vijayakumar, MS2, Sriram Krishnaswami, PhD3, Manish Gupta, PhD1, John Mondick, PhD1, Bhuvana Jayaraman, BS1, Arun Muralidharan, BS1, Srinivas Santhanam, MS1 and S. Vijayakumar, PhD2 iClinical: NONMEM Workbench |
| Vis, Peter (1), Vanitha Sekar (2), Erno van Schaick (1) and Richard Hoetelmans (3) Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects after administration of TMC114 in combination with low dose ritonavir |
| Wallin, Johan E, Friberg Lena E., Karlsson Mats O. An Adaptive Dosing Tool For Etoposide Using Neutrophil Counts Based on a Semi-Physiological Model |
| Weatherley B., L. McFadyen, P. Milligan Population Analysis of Maraviroc Phase 1 Noncompartmental Pharmacokinetic Data |
| Wilkins, Justin J (1), Karlsson, Mats O (1), Jonsson, E Niclas (2) Patterns and power for the visual predictive check |
| Wilkins, Justin J (1), Hooker, Andrew (1), Karlsson, Mats O (1), Jonsson, E Niclas (2) Xpose – an R-based population pharmacokinetic/pharmacodynamic model-building aid for NONMEM |
| William Faltaos, D (1), S. Urien (1), V.Morel (2), G. Kaloshi (3), k. Hoang Xuan (3), V.Leblond (2), Philippe Lechat (1). Population pharmacokinetic study of methotrexate in patient with lymphoid malignancy |
| Willmann, Stefan, Wolfgang Weiss, Andrea N. Edginton Hands-On Demonstrations of the Physiology-Based Pharmacokinetic Software, PK-Sim® |
| Willmann, Stefan, Andrea N. Edginton, Walter Schmitt, Marcus Kleine-Besten, and Jennifer B. Dressman Simulating Oral Absorption with PK-Sim®: Methodology and Application Examples |
| Woltosz, Walter S. and Michael B. Bolger Simulation of the Nonlinear PK of Gabapentin and Midazolam in Adult and Pediatric Populations |
| Yim, Dong-Seok (1), Dong-Gun Lee, Su-Mi Choi, Wan-Shik Shin, Hyon-oh Lah(1) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea |
| Zandvliet, Anthe S.(1), Alwin D.R. Huitema (1), William Copalu (2), Yasuhide Yamada (3), Tomohide Tamura (3), Jos H. Beijnen (1,4) , Jan H.M. Schellens (4,5) Pharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity |
| Zandvliet, Anthe S. (1), Wandena S. Siegel-Lakhai (1), Jan H.M. Schellens (2,3), William Copalu (4), Gerard Milano (5), Jos H. Beijnen (1,3), Alwin D.R. Huitema (1) Semi-mechanistic PK/PD model of indisulam in combination with capecitabine: a time-dependent pharmacokinetic interaction contributes to excessive hematological toxicity |
